These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 12605370

  • 1. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
    Massi D, Franchi A, Ketabchi S, Paglierani M, Pimpinelli N, Santucci M.
    Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
    [Abstract] [Full Text] [Related]

  • 2. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
    Voland P, Besig S, Rad R, Braun T, Baur DM, Perren A, Langer R, Höfler H, Prinz C.
    Neuroendocrinology; 2009 Jan; 89(1):66-78. PubMed ID: 18708724
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
    Ozen O, Krebs B, Hemmerlein B, Pekrun A, Kretzschmar H, Herms J.
    Clin Cancer Res; 2004 Jul 15; 10(14):4746-53. PubMed ID: 15269148
    [Abstract] [Full Text] [Related]

  • 6. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A.
    Hum Pathol; 2008 Feb 15; 39(2):217-23. PubMed ID: 17949787
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer.
    Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS.
    J Pathol; 2000 Feb 15; 190(2):150-6. PubMed ID: 10657012
    [Abstract] [Full Text] [Related]

  • 9. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
    Matsunaga Y, Koda M, Murawaki Y.
    Res Commun Mol Pathol Pharmacol; 2004 Feb 15; 115-116():143-50. PubMed ID: 17564313
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Expression of metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 in transitional cell carcinoma of upper urinary tract: correlation with tumor stage and survival.
    Miyata Y, Kanda S, Nomata K, Hayashida Y, Kanetake H.
    Urology; 2004 Mar 15; 63(3):602-8. PubMed ID: 15028476
    [Abstract] [Full Text] [Related]

  • 14. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
    Wan Y, Wei Q, Pan Y, Liu Y.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 15; 38(7):510-3. PubMed ID: 11832095
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
    Kawata N, Nagane Y, Hirakata H, Ichinose T, Okada Y, Yamaguchi K, Takahashi S.
    Urology; 2007 Jun 15; 69(6):1049-53. PubMed ID: 17572184
    [Abstract] [Full Text] [Related]

  • 17. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinase, collagens, and Ki67 antigen in pleural malignant mesothelioma: an immunohistochemical and electron microscopic study.
    Hirano H, Tsuji M, Kizaki T, Sashikata T, Yoshi Y, Okada Y, Mori H.
    Med Electron Microsc; 2002 Mar 15; 35(1):16-23. PubMed ID: 12111403
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
    Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeenniemi-Hujanen T.
    Cancer Lett; 2006 May 08; 236(1):125-32. PubMed ID: 15982804
    [Abstract] [Full Text] [Related]

  • 20. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
    Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.
    Cancer; 2005 Apr 15; 103(8):1676-84. PubMed ID: 15754326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.